Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi

Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights.EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) — The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK inhibitors, continue displace long-standing therapies like TNF inhibitors. With the recent FDA approvals of Tremfya (guselkuma